Context: The BRAF mutation may influence the expression patterns of molecular markers
that are related to the development and progression of thyroid cancer. Objective: The …

Background: Activating mutations of the BRAF gene have recently been reported in thyroid
carcinomas. In particular, V600E mutation is highly prevalent in papillary thyroid carcinoma …

Aim BRAF mutation inhibits many tumour suppressor genes, increases pro-angiogenic
molecules and reduces radioactive iodine uptake of tumour in papillary thyroid cancer …

Context: Because very few studies have examined the correlation between BRAF mutations
and clinicopathological features of papillary thyroid carcinoma (PTC), we analyzed here a …

BACKGROUND: The incidence of thyroid cancer has doubled over the past decade. The
reason for this dramatic increase in incidence is controversial. Some investigators have …

Context: Use of BRAF mutation in papillary thyroid cancer (PTC) has the potential to improve
risk stratification of this cancer. Objective: The objective of the study was to investigate the …

Papillary thyroid cancer (PTC) constitutes more than 90% of the thyroid cancers. MAP
kinase/ERK pathway plays an important role in the development of several cancers. BRAF …

Background: The BRAFV600E mutation is the most frequent genetic alteration in papillary
thyroid carcinoma (PTC). The role of BRAFV600E mutation as a poor prognostic factor has …

Context: The relevance of the BRAF V600E mutation in papillary thyroid carcinoma (PTC) as
a negative prognostic factor is a subject of intense debate. This mutation has been …

Objective: To examine the prevalence of BRAF mutation among thyroid cancer histologic
subtypes and determine the association of BRAF mutation with indicators of poor prognosis …